Technical Analysis for LADX - Ladrx Corp
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.6000 | 7.38% | 0.1100 |
LADX closed up 7.38 percent on Tuesday, September 19, 2023, on 7 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 7.38% | |
New 52 Week Closing Low | Bearish | 7.38% | |
180 Bearish Setup | Bearish Swing Setup | 7.38% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Chemotherapy Cancer Treatments Antineoplastic Drugs Aldoxorubicin Cytrx Regulus Therapeutics
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Chemotherapy Cancer Treatments Antineoplastic Drugs Aldoxorubicin Cytrx Regulus Therapeutics
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 22.0 |
52 Week Low | 1.49 |
Average Volume | 1,479 |
200-Day Moving Average | 8.7395 |
50-Day Moving Average | 2.0997 |
20-Day Moving Average | 1.8735 |
10-Day Moving Average | 1.7700 |
Average True Range | 0.1970 |
RSI (14) | 38.65 |
ADX | 15.57 |
+DI | 28.6288 |
-DI | 42.0301 |
Chandelier Exit (Long, 3 ATRs) | 1.7490 |
Chandelier Exit (Short, 3 ATRs) | 2.0810 |
Upper Bollinger Bands | 2.2369 |
Lower Bollinger Band | 1.5101 |
Percent B (%b) | 0.12 |
BandWidth | 38.7937 |
MACD Line | -0.2430 |
MACD Signal Line | -0.2402 |
MACD Histogram | -0.0028 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.6000 | ||||
Resistance 3 (R3) | 1.6000 | 1.6000 | 1.6000 | ||
Resistance 2 (R2) | 1.6000 | 1.6000 | 1.6000 | 1.6000 | |
Resistance 1 (R1) | 1.6000 | 1.6000 | 1.6000 | 1.6000 | 1.6000 |
Pivot Point | 1.6000 | 1.6000 | 1.6000 | 1.6000 | 1.6000 |
Support 1 (S1) | 1.6000 | 1.6000 | 1.6000 | 1.6000 | 1.6000 |
Support 2 (S2) | 1.6000 | 1.6000 | 1.6000 | 1.6000 | |
Support 3 (S3) | 1.6000 | 1.6000 | 1.6000 | ||
Support 4 (S4) | 1.6000 |